$-0.29 EPS Expected for Q BioMed Inc. (QBIO) as of July, 18

June 27, 2018 - By Sarah Holford

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

Q BioMed Inc. (OTCMKTS:QBIO)’s earnings report is expected by WallStreet on July, 18, Zacks reports. Analysts predict 0.00 % diference or $-0.29 from the $-0.29 EPS from 2017. 70.59 % negative EPS growth is what analysts predict. $-0.17 earnings per share was reported for last quarter. Ticker’s shares touched $3.42 during the last trading session after 0.29% change.Q BioMed Inc. has volume of 16,791 shares. Since June 27, 2017 QBIO has 0.00% and is . QBIO underperformed the S&P500 by 12.57%.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The firm is valued at $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: